Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 31, 2022
Discovery & Translation

Maze identifies two regulators of ALS target ATXN2; plus updates from Black Diamond and more

BioCentury’s roundup of translational news
BioCentury | May 15, 2018
Distillery Therapeutics

Neurology

BioCentury | Jan 11, 2017
Distillery Therapeutics

Neurology

BioCentury | Jan 7, 2016
Strategy

Imaging

BioCentury | May 12, 2014
Clinical News

NGR-hTNF: Phase III data

BioCentury | May 12, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones
BioCentury | Jun 3, 2013
Clinical News

NGR-hTNF: Additional Phase II data

BioCentury | Jun 3, 2013
Clinical News

NGR-hTNF: Interim Phase II data

BioCentury | Dec 24, 2012
Clinical News

NGR-hTNF: Completed Phase III enrollment

Items per page:
1 - 10 of 54